Lamina Dura Thickening and MRONJ Risk

confidence: high · 7 sources

⚠
Working research — not a recommendation.

This page records what the evidence says a policy does, not what anyone should do about it. It has been synthesized from the cited sources but has not been independently reviewed.

What the evidence says

Antiresorptive drug (ARD) therapy increases the prevalence of lamina dura thickening. Three studies from one research group compare treated patients with controls. A retrospective longitudinal cohort found thickening in 10% of treated patients and 3% of controls (p = 0.003). A case-control study found 12% versus 3% before surgery (p<0.001). A second case-control study of oncologic patients at tooth extraction sites found 78.2% (68/87) in the study group versus 18.9% (20/106) in controls. All three agree on direction. The magnitudes differ widely, and the sources do not say why.

The thickening develops over time on treatment. In a retrospective longitudinal cohort (n=65 per group), lamina dura thickness stayed stable in controls and increased in ARD-treated patients (p < 0.001). Within the ARD group, 30.6% showed no change, 55.4% developed mild thickening and 13.8% developed marked thickening. In controls, 9.2% developed mild thickening. The median time to thickening was 27 months, with an estimated survival probability of 0.49 (95% CI 0.38–0.64). A systematic review lists thickening of the lamina dura among the early bone changes of antiresorptive therapy. It says the timepoint of occurrence and the relation to dosing are not clear.

After tooth extraction, the lamina dura persists more often in ARD-treated patients. The 2022 cohort reports this at p < 0.001. The 2023 case-control study reports persistence in 65% of the study group (p<0.001).

Whether thickening predicts osteonecrosis of the jaw (MRONJ) is where the evidence weakens. The 2022 cohort ran a multivariate analysis with correction for multiple testing. Only absence of a periapical lesion (OR = 1.78), angular bone defect (OR = 1.72) and a sclerotic bone pattern (OR = 3.45) kept their results. Lamina dura thickening did not. The longitudinal cohort found no direct association with MRONJ (p = 0.39). The 2023 case-control study found no difference between patients who did and did not develop osteonecrosis. That study reports this as consistent with earlier work and does not give a p-value for it. The systematic review states that the potential MRONJ risk of these findings is not clear. A 2025 review says thickening may support a diagnosis of stage 0 MRONJ. That is a diagnostic statement, not a risk estimate.

In a cross-sectional study of patients who already had MRONJ, thickening appeared in less than half of both panoramic radiographs and cone-beam CT images. Panoramic radiography and cone-beam CT did not differ in detecting it (p > 0.05). Thickening was more frequent in patients on oral than on intravenous bisphosphonates, but the difference was not statistically reliable (p > 0.05).

Where the evidence splits

Yarom (2025) says thickening of the lamina dura was more frequently observed in patients who eventually developed MRONJ. The 2022 multivariate analysis, the longitudinal cohort (p = 0.39) and the 2023 case-control study found no such association. The sources on this page do not explain the split. The 2025 statement comes from a review that cites other original studies. It gives no prevalence or odds ratio, so it cannot be compared with the cohort estimates.

The prevalence of thickening in treated patients ranges from 10% and 12% to 78.2%. The only difference the claims name is that the 78.2% study was run at a specialized referral center with a high concentration of MRONJ cases, which may not generalize. Whether that accounts for the gap is not tested in these sources.

The 2025 cross-sectional study found thickening in less than half of MRONJ patients. It describes this as lower than earlier reports that called it a common finding. Whether this reflects a true lower prevalence or limited tooth availability for evaluation is unresolved in the source.

Thresholds and dose-response

No threshold established in the current sources.

Open empirical questions

Findings

ARD therapy increases the prevalence of lamina dura thickening relative to untreated controls

confidence — direction: highconfidence — magnitude: mediumconsensus: settled on direction; magnitude varies by study
mechanism
not established in the claims; thickening is described as a radiographic bone change that accompanies antiresorptive therapy
effect
increases prevalence: 10% vs 3% (cohort); 12% vs 3% (case-control); 78.2% (68/87) vs 18.9% (20/106) at extraction sites (case-control)
conditions / moderators
the 78.2% figure comes from a referral center with many MRONJ cases and may not generalize; other moderators not established

ARD therapy increases lamina dura thickness progressively over time

confidence — direction: highconfidence — magnitude: mediumconsensus: thin; one cohort gives the time-course figures
mechanism
not established in the claims
effect
increases thickness in ARD-treated patients, stable in controls (p < 0.001); 30.6% no change, 55.4% mild thickening, 13.8% marked thickening vs 9.2% mild thickening in controls; median time to thickening 27 months (survival probability 0.49, 95% CI 0.38–0.64)
conditions / moderators
single-center study, n=65 per group, variable retrospective follow-up intervals; the wide interval reflects that design

ARD therapy increases persistence of the lamina dura after tooth extraction

confidence — direction: highconfidence — magnitude: mediumconsensus: settled on direction; two studies from the same group
mechanism
not established in the claims
effect
increases prevalence: p < 0.001 in the 2022 cohort; 65% persistence in the treated group in the 2023 case-control study (p<0.001)
conditions / moderators
not established

Lamina dura thickening shows no measured association with MRONJ development in the cohort and case-control studies

confidence — direction: mediumconfidence — magnitude: lowconsensus: contested; the weight of the quantified studies leans toward no association
mechanism
not established
effect
no measured effect: absent from the multivariate predictors after correction for multiple testing (2022); p = 0.39 (2026); no difference between patients with and without osteonecrosis (2023, no p-value reported)
conditions / moderators
unequal group sizes and a small sample may limit power; Yarom (2025) reports the opposite direction without quantification

Lamina dura thickening is a radiographic finding that may support a stage 0 MRONJ diagnosis

confidence — direction: mediumconfidence — magnitude: lowconsensus: thin; earlier reports of thickening as common are not matched by the 2025 cross-sectional detection rate
mechanism
not established
effect
diagnostic support only ("may support"); thickening was detected in less than half of MRONJ patients on both panoramic radiography and cone-beam CT
conditions / moderators
the two modalities did not differ (p > 0.05); more frequent in oral than intravenous bisphosphonate users, but the difference was not statistically reliable (p > 0.05)